Strategies to Prevent Cast Formation in Patients with Plastic Bronchitis Undergoing Heart Transplantation

Pediatr Cardiol. 2017 Jun;38(5):1077-1079. doi: 10.1007/s00246-017-1568-y. Epub 2017 Jan 19.

Abstract

Plastic bronchitis, a rare complication after Fontan palliation, carries a high morbidity and mortality risk. Heart transplantation is an effective treatment option, but casts may occur in the early post-operative period. We present a case series detailing peri-operative management strategies to minimize morbidity and mortality related to plastic bronchitis in patients undergoing heart transplantation. Patient 1 received no treatment pre-, intra-, or post-transplant for prevention of bronchial casts and developed severe respiratory acidosis 18 h following transplant. Emergent bronchoscopy was performed and a large obstructive cast was removed. The patient recovered and received inhaled tissue plasminogen activator (tPA) for 5 days. Patient 2 received inhaled tPA before, during, and for 5 days after transplantation and no bronchial casts developed. Patient 3 underwent intraoperative bronchoscopy just prior to implantation revealing no casts. The patient underwent non-urgent, preemptive bronchoscopy on post-transplant days 1, 3, and 4, removing several partially obstructive bronchial blood clots/casts, with no casts thereafter. Heart transplantation results in eventual resolution of plastic bronchitis. Residual bronchial casts can still be problematic in the peri-operative period. Airway clearance with inhaled tPA or bronchoscopy may prevent the need for prolonged mechanical ventilation and reduce post-operative morbidity in this unique population.

Keywords: Fontan; Pediatric heart transplantation; Plastic bronchitis; Single ventricle.

Publication types

  • Case Reports

MeSH terms

  • Administration, Inhalation
  • Airway Obstruction / prevention & control
  • Airway Obstruction / therapy*
  • Bronchitis / etiology
  • Bronchitis / therapy*
  • Bronchoscopy
  • Child
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fontan Procedure / adverse effects
  • Heart Defects, Congenital / complications
  • Heart Defects, Congenital / surgery*
  • Heart Transplantation*
  • Humans
  • Male
  • Tissue Plasminogen Activator / administration & dosage

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator